Zhiquan Liu

Zhiquan Liu

Auto-generated profile, based on publicly available information

Zhiquan Liu

Department of Ophthalmology, Stanford University School of Medicine

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 July 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
ZLZhiquan Liu
Zhiquan Liu
MCMao Chen
Mao Chen
SCSiyu Chen
Siyu Chen
JDJichao Deng
Jichao Deng
YSYuning Song
Yuning Song
ZLZhanjun Li
Zhanjun Li
Cytidine base editors (CBEs) and adenine base editors (ABEs), composed of a cytidine deaminase or an evolved adenine deaminase fused to Cas9 nickase, enable the conversion of C·G to T·A or A·T to G·C base pair in organisms, respectively. Here, we show that BE3 and ABE7.10 systems can achieve a targeted mutation efficiency of 53–88% and 44–100%, respectively, in both blastocysts and Founder (F0) rabbits. Meanwhile, this strategy can be used to precisely mimic human pathologies by efficiently inducing nonsense or missense mutations as well as RNA mis-splicing in rabbit. In addition, the reduced frequencies of indels with higher product purity are also determined in rabbit blastocysts by BE4-Gam, which is an updated version of the BE3 system. Collectively, this work provides a simple and efficient method for targeted point mutations and generation of disease models in rabbit.

9 May 2019 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
ZLZhiquan Liu
Zhiquan Liu
HSHuanhuan Shan
Huanhuan Shan
SCSiyu Chen
Siyu Chen
MCMao Chen
Mao Chen
QZQuanjun Zhang
Quanjun Zhang
ZLZhanjun Li
Zhanjun Li
Cytidine base editors, which are composed of a cytidine deaminase fused to clustered regularly interspaced short palindromic repeat (CRISPR)–associated protein 9 (Cas9) nickase, enable the efficient conversion of the C·G base pair to T·A in various organisms. However, the currently used rat apolipoprotein B mRNA‐editing enzyme, catalytic polypeptide 1(rA1)–based BE3 is often inefficient in target Cs that are immediately downstream of a G (GC context). Here, we observed that, with an 11‐nt editing window, an optimized activation‐induced cytidine deaminase (AID)‐Cas9 fusion can efficiently convert C to T in a variety of sequence contexts in rabbits. Strikingly, the enhanced AID‐Cas9 fusion (eAID‐BE4max) has significant effectiveness of inducing Tyr p.R299H mutation in GC contexts (from 16.67 to 83.33%) in comparison with BE3 in founder rabbits. Furthermore, the engineered AID‐Cas9 variants were produced with reduced bystander activity [eAID (N51G)‐BE4max] and increased genome‐targeting scope (eAID‐NG‐BE4max). Overall, this work provides a series of improved tools that were generated using optimized AID‐Cas9 fusions and associated engineered variants that can be used for efficient and versatile C‐to‐T base editing, especially in GC contexts.—Liu, Z., Shan, H., Chen, S., Chen, M., Zhang, Q., Lai, L., Li, Z. Improved base editor for efficient editing in GC contexts in rabbits with an optimized AID‐Cas9 fusion. FASEB J. 33, 9210–9219 (2019). www.fasebj.org

11 June 2019 in Cell Discovery
Verified
Journal Article
Open access
PDF file
ZLZhiquan Liu
Zhiquan Liu
SCSiyu Chen
Siyu Chen
HSHuanhuan Shan
Huanhuan Shan
QZQuanjun Zhang
Quanjun Zhang
MCMao Chen
Mao Chen
ZLZhanjun Li
Zhanjun Li

1 February 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
ZLZhiquan Liu
Zhiquan Liu
SCSiyu Chen
Siyu Chen
LLLiangxue Lai
Liangxue Lai
ZLZhanjun Li
Zhanjun Li
Cytosine base editors (CBEs), combining cytidine deaminases with the Cas9 nickase (nCas9), enable targeted C-to-T conversions in genomic DNA and are powerful genome-editing tools used in biotechnology and medicine. However, the overexpression of cytidine deaminases in vivo leads to unexpected potential safety risks, such as Cas9-independent off-target effects. This risk makes the development of deaminase off switches for modulating CBE activity an urgent need. Here, we report the repurpose of four virus-derived anti-deaminases (Ades) that efficiently inhibit APOBEC3 deaminase-CBEs. We demonstrate that they antagonize CBEs by inhibiting the APOBEC3 catalytic domain, relocating the deaminases to the extranuclear region or degrading the whole CBE complex. By rationally engineering the deaminase domain, other frequently used base editors, such as CGBE, A&CBE, A&CGBE, rA1-CBE and ABE8e, can be moderately inhibited by Ades, expanding the scope of their applications. As a proof of concept, the Ades in this study dramatically decrease both Cas9-dependent and Cas9-independent off-target effects of CBEs better than traditional anti-CRISPRs (Acrs). Finally, we report the creation of a cell type-specific CBE-ON switch based on a microRNA-responsive Ade vector, showing its practicality. In summary, these natural deaminase-specific Ades are tools that can be used to regulate the genome-engineering functions of BEs.

19 September 2024 in Advanced Science
Verified
Journal Article
Open access
ZLZhiquan Liu
Zhiquan Liu
SCSiyu Chen
Siyu Chen
ADAlexander E. Davis
Alexander E. Davis
CLChien‐Hui Lo
Chien‐Hui Lo
QWQing Wang
Qing Wang
YSYang Sun
Yang Sun
Retinitis pigmentosa (RP) is a complex spectrum of inherited retinal diseases marked by the gradual loss of photoreceptor cells, ultimately leading to blindness. Among these, mutations in PDE6A, responsible for encoding a cGMP‐specific phosphodiesterase, stand out as pivotal in autosomal recessive RP (RP43). Unfortunately, no effective therapy currently exists for this specific form of RP. However, recent advancements in genome editing, such as base editing (BE) and prime editing (PE), offer a promising avenue for precise and efficient gene therapy. Here, it is illustrated that the engineered BE and PE systems, particularly PE, exhibit high efficiency in rescuing a target point mutation with minimal bystander effects in an RP mouse model carrying the Pde6a (c.2009A > G, p.D670G) mutation. The optimized BE and PE systems are first screened in N2a cells and subsequently assessed in electroporated mouse retinas. Notably, the optimal PE system, delivered via dual adeno‐associated virus (AAV), precisely corrects the pathogenic mutation with average 9.4% efficiency, with no detectable bystander editing. This correction restores PDE6A protein expression, preserved photoreceptors, and rescued retinal function in Pde6a mice. Therefore, this study offers a proof‐of‐concept demonstration for the treatment of Pde6a‐related retinal degeneration using BE and PE systems.

2 June 2025 in PNAS Nexus
Verified
Journal Article
Open access
SCSiyu Chen
Siyu Chen
ZLZhiquan Liu
Zhiquan Liu
CLChien-Hui Lo
Chien-Hui Lo
QWQing Wang
Qing Wang
KNKe Ning
Ke Ning
YSYang Sun
Yang Sun
Glaucoma is a major global cause of irreversible vision loss. It is marked by elevated intraocular pressure (IOP) and the loss of retinal ganglion cells (RGC). While there are medical and surgical therapies for glaucoma aiming to reduce aqueous humor production or enhance its drainage, these treatments are often inadequate for effectively managing the disease. In this study, we developed a targeted therapy for glaucoma by knocking down two genes associated with aqueous humor production (aquaporin 1 [AQP1] and carbonic anhydrase type 2 [CA2]) using Cas13 RNA editing systems. We demonstrate that hfCas13d-mediated knockdown of AQP1 and CA2 significantly lowers IOP in wild-type mice and in a corticosteroid-induced glaucoma mouse model. We show that the lowered IOP results from decreasing aqueous production without affecting the outflow facility; this treatment also significantly promotes RGC survival as compared with untreated control groups. Therefore, CRISPR–Cas-based gene editing may be an effective treatment to lower IOP for glaucomatous optic neuropathy.